Investors

Press Releases

Date Title View
Toggle Summary Momenta Pharmaceuticals to Present at CIBC World Markets Fifteenth Annual Healthcare Conference
Momenta Pharmaceuticals to Present at CIBC World Markets Fifteenth Annual Healthcare Conference CAMBRIDGE, Mass., Oct. 29 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on sugar sequencing technology, announced today that its
View HTML
Toggle Summary Momenta Pharmaceuticals to Webcast Conference Call Discussing Third Quarter 2004 Financial Results
Momenta Pharmaceuticals to Webcast Conference Call Discussing Third Quarter 2004 Financial Results CAMBRIDGE, Mass., Oct. 28 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on sugar sequencing technology, will report financial
View HTML
Toggle Summary Momenta Pharmaceuticals' Technology Featured in Nature Reviews
Momenta Pharmaceuticals' Technology Featured in Nature Reviews Article Highlights the Potential of Sugars for Therapeutic Drug Development CAMBRIDGE, Mass., Oct. 12 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on sugar
View HTML
Toggle Summary Momenta Pharmaceuticals To Be Included in Russell 3000(R) Index
Momenta Pharmaceuticals To Be Included in Russell 3000(R) Index CAMBRIDGE, Mass., Sept. 16 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) announced today that it will be included in the Russell 3000 Index when the Index is reconstituted effective October 1, 2004 to reflect
View HTML
Toggle Summary Momenta Pharmaceuticals to Present at ThinkEquity Partners Growth Conference
Momenta Pharmaceuticals to Present at ThinkEquity Partners Growth Conference CAMBRIDGE, Mass., Sept. 14 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on sugar sequencing technology, announced today that its Chairman and Chief
View HTML
Toggle Summary Momenta Pharmaceuticals to Webcast Presentation at Bear Stearns 17th Annual Healthcare Conference
Momenta Pharmaceuticals to Webcast Presentation at Bear Stearns 17th Annual Healthcare Conference CAMBRIDGE, Mass., Sept. 2 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on sugar sequencing technology, announced today that its
View HTML
Toggle Summary Momenta Pharmaceuticals Reports Financial Results for Second Quarter 2004
Momenta Pharmaceuticals Reports Financial Results for Second Quarter 2004 CAMBRIDGE, Mass., Aug. 16 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on sugar sequencing technology, today announced its financial results for the
View HTML
Toggle Summary Momenta Pharmaceuticals to Webcast Presentation at Banc of America Securities 'New Products, New Paradigms in Health Care' Conference
Momenta Pharmaceuticals to Webcast Presentation at Banc of America Securities 'New Products, New Paradigms in Health Care' Conference CAMBRIDGE, Mass., July 23 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) announced today that its Chairman and Chief Executive Officer Alan
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Exercise of Over-Allotment Option
Momenta Pharmaceuticals Announces Exercise of Over-Allotment Option CAMBRIDGE, MA - June 28, 2004 – Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) announced today that the underwriters of the Company's recent initial public offering of 5,350,000 shares of common stock exercised in full their
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Pricing of Initial Public Offering
Momenta Pharmaceuticals Announces Pricing of Initial Public Offering CAMBRIDGE, Mass., June 21 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. announced today the pricing of its initial public offering of 5,350,000 shares of common stock at a price of $6.50 per share.
View HTML